Italian Multicenter Study on Low-Density Lipoprotein Apheresis: Retrospective Analysis (2007)
- 1 February 2010
- journal article
- research article
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 14 (1) , 79-86
- https://doi.org/10.1111/j.1744-9987.2009.00704.x
Abstract
A retrospective study--the Italian Multicenter Study on Low-density Lipoprotein Apheresis (IMS-LDLa)--was carried out, which involved 19 centers for LDLa in Italy, distributed all over the country--in the north, center, south, and the major islands. The survey was conducted through two consecutive questionnaires, which can be downloaded online from a dedicated site. The total number of procedures performed until 2007 was 31 012, and the number of patients undergoing treatment until 2007 were 229. The treated patients still surviving consisted of 136 (74 males and 62 females); those surviving but not treated numbered 95, and those deceased numbered 14. The techniques utilized, listed by frequency of use, were the following: dextran sulfate cellulose adsorption, direct adsorption of lipids (DALI), heparin extracorporeal LDL precipitation, immunoadsorption, plasma-exchange, cascade filtration, and Lipocollect 200. The mean treated plasma and blood volumes per session were 3916.5 mL and 8735.1 mL, respectively. The most frequently utilized vascular access points were: venous 84.4% and arteriovenous fistula 15.5%. Hematoma by venipuncture (230 episodes), low outlet flow (125 episodes), and circuit coagulation (44 episodes) were reported as to be the most frequent side effects. In the second questionnaire (filled in by 19 centers) the centers were asked to report their data on: quality diagnosis of dyslipidemia and referents for genetic-molecular and clinical diagnosis, cholesterol-lowering drugs and dosages, typology of cardiovascular check-ups at the beginning of treatment and in follow-up, non-cholesterol-lowering drugs with priority for cardiologic drugs, including oral anti-coagulants, and, lastly, information related to the appropriateness of curing patients still under treatment with LDLa and, where possible, news on patients no longer under treatment.Keywords
This publication has 30 references indexed in Scilit:
- Plasmapheresis in asparaginase‐induced hypertriglyceridemiaTransfusion, 2008
- Recommendations for the use of LDL apheresisPublished by Elsevier ,2008
- Guidelines on the use of therapeutic apheresis in clinical practice—Evidence‐based approach from the apheresis applications committee of the American society for apheresisJournal of Clinical Apheresis, 2007
- Genetic determinants of statin intoleranceLipids in Health and Disease, 2007
- Direct Adsorption of Low‐Density Lipoprotein by DALI‐LDL‐Apheresis: Results of a Prospective Long‐term Multicenter Follow‐up Covering 12 291 SessionsTherapeutic Apheresis and Dialysis, 2006
- The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapyAtherosclerosis, 2006
- Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statinsAtherosclerosis, 2005
- Why some patients respond poorly to statins and how this might be remediedPublished by Oxford University Press (OUP) ,2002
- Determinants of Variable Response to Statin Treatment in Patients With Refractory Familial HypercholesterolemiaArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- LDL-Apheresis Atherosclerosis Regression Study (LAARS)Circulation, 1996